Results 141 to 150 of about 13,185,214 (212)

Toxicodermia generalizada secundaria a la administración de anfotericina B liposomal

Farmacia Hospitalaria, 2010
J.C. de Miguel-Bouzas, L. Herrero-Poch, G. Piñeiro-Corrales   +2 more
openaire   +1 more source

TERAPIA PROFILÁTICA COM ANFOTERICINA B LIPOSSOMAL NA RECORRÊNCIA DA LEISHMANIOSE MUCOCUTÂNEA. RELATO DE EXPERIÊNCIA BEM‐SUCEDIDA EM PACIENTE PORTADOR DE ESPONDILITE ANQUILOSANTE PRIMÁRIA EM USO DE ANTI‐TNF

Brazilian Journal of Infectious Diseases, 2018
Daniel Fernandes Duailibi, Diego Feriani, Regina Maia de Souza, H. F. A. Junior, Rui Imamura, Pablo Muños Torres, V. Amato   +6 more
semanticscholar   +1 more source

Oral mucormycosis associated with COVID-19 and diabetes mellitus: Case report and literature review [PDF]

Biomedica
Velasco JC, Vargas LJ, García L, Torres IJ, González IC.   +4 more
europepmc   +1 more source

[Intracardiac fungal mass in extreme premature patient]. [PDF]

Arch Peru Cardiol Cir Cardiovasc, 2022
Diaz Rojas MC, Peralta Rodríguez JE, Soto Béjar OA.   +2 more
europepmc   +1 more source

Estudo de subemulsões e microemulsões contendo anfotericina B para administração oral

, 2014
The objective of this work was the development of subemulsified and microemulsified systems stabilized by soya phosphatidylcholine (FS) and/or FS associated to hydrophylic surfactants to AmB veiculation. It was evaluated the use of pluronic (PLU) as co-surfactant and it was observed the predominancy of the more viscose systems.
openaire   +1 more source

[Eumycetomas by Fusarium oxysporum and Madurella mycetomatis. Description of two cases and literature review]. [PDF]

Rev Esp Quimioter, 2022
Martínez López D, Pérez Blasco A, García Ferrer L, Camarena JJ, González R, Rodrigo Perez JL.   +5 more
europepmc   +1 more source

Desenvolvimento e avaliação de nova preparação de anfotericina B e/ou cetoconazol em dispersão de bixina, pullulan e trealose

, 2019
G. Takata
semanticscholar   +1 more source

Disseminated histoplasmosis with skin manifestations in advanced HIV: Case report. [PDF]

Rev Med Inst Mex Seguro Soc
Arreola-Banda F, López-Lachica O, García-Maldonado G, Alcázar-Quiñones CS, Rodríguez-Alejandro P, Castillo-Meraz JA.   +5 more
europepmc   +1 more source

Cost-effectiveness study of therapeutic approaches for mucosal leishmaniasis. [PDF]

Cad Saude Publica
Carvalho JP, Cota G, Freire ML, Galvão EL, Silva SN, Assis TSM.   +5 more
europepmc   +1 more source

[Cryptococcus albidus, Naganishia albida, primary skin infection, first case reported in Mexico]. [PDF]

Rev Med Inst Mex Seguro Soc
Corona-Rosas MF, Alcalá-Alegría APC, Triana-González S, Gaitán-Martínez J, Procopio-Velázquez J.   +4 more
europepmc   +1 more source